Skip to main content
Premium Trial:

Request an Annual Quote

SuperNova Diagnostics, Concile Reach European Co-marketing Deal

NEW YORK (GenomeWeb News) – Point-of-care firm SuperNova Diagnostics today announced a co-marketing deal with Concile for a test that assesses "various deficiencies" relating to wellness and chronic diseases.

The terms of the deal gives Concile, a German diagnostic development and distribution firm, the rights to co-market SuperNova's test in Europe. SuperNova will develop and manufacture the test, secure regulatory approvals, and co-market it.

Concile will provide SuperNova upfront payments, milestone development payments, and share revenues for sales within the European Union. SuperNova retains all marketing rights outside of the EU, it said.

Neil Campbell, president and CEO of SuperNova, said in a statement, "The partnership and sales reach of Concile gives us a focused entry into the European market with an established leader and also allows us to build our commercial business into other markets."

Financial terms were not disclosed.

Headquartered in German Town, Md., SuperNova is a development stage firm whose main technology is a nanochemistry-based DNA amplification method it calls AmpCrystal that achieves "ultra-low sensitivity and specificity while not sacrificing a dynamic range of measurements," it said.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more